Acute On Chronic Liver Failure Aclf Market

DelveInsight's "Acute On Chronic Liver Failure (ACLF) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute On Chronic Liver Failure (ACLF) , historical and forecasted epidemiology as well as the Acute On Chronic Liver Failure (ACLF) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Acute On Chronic Liver Failure (ACLF) market report provides current treatment practices, emerging drugs, Acute On Chronic Liver Failure (ACLF) market share of the individual therapies, current and forecasted Acute On Chronic Liver Failure (ACLF) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute On Chronic Liver Failure (ACLF) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acute On Chronic Liver Failure (ACLF) Disease Understanding and Treatment Algorithm

The DelveInsight Acute On Chronic Liver Failure (ACLF) market report gives a thorough understanding of the Acute On Chronic Liver Failure (ACLF) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 


Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Acute On Chronic Liver Failure (ACLF) . 


Treatment 

It covers the details of conventional and current medical therapies available in the Acute On Chronic Liver Failure (ACLF) market for the treatment of the condition. It also provides Acute On Chronic Liver Failure (ACLF) treatment algorithms and guidelines in the United States, Europe, and Japan. 

Acute On Chronic Liver Failure (ACLF) Epidemiology  

The Acute On Chronic Liver Failure (ACLF) epidemiology division provide insights about historical and current Acute On Chronic Liver Failure (ACLF) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Acute On Chronic Liver Failure (ACLF) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 


Country Wise- Acute On Chronic Liver Failure (ACLF) Epidemiology 

The epidemiology segment also provides the Acute On Chronic Liver Failure (ACLF) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Acute On Chronic Liver Failure (ACLF) Drug Chapters

Drug chapter segment of the Acute On Chronic Liver Failure (ACLF) report encloses the detailed analysis of Acute On Chronic Liver Failure (ACLF) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Acute On Chronic Liver Failure (ACLF) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Marketed Drugs 

The report provides the details of the marketed product available for Acute On Chronic Liver Failure (ACLF) treatment. 


Acute On Chronic Liver Failure (ACLF) Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Acute On Chronic Liver Failure (ACLF) treatment. 

Acute On Chronic Liver Failure (ACLF) Market Outlook

The Acute On Chronic Liver Failure (ACLF) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Acute On Chronic Liver Failure (ACLF) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 


This segment gives a thorough detail of Acute On Chronic Liver Failure (ACLF) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 


According to DelveInsight, Acute On Chronic Liver Failure (ACLF) market in 7MM is expected to change in the study period 2017-2030.


Key Findings

This section includes a glimpse of the Acute On Chronic Liver Failure (ACLF) market in 7MM.


The United States Market Outlook

This section provides the total Acute On Chronic Liver Failure (ACLF) market size and market size by therapies in the United States.


EU-5 Countries: Market Outlook

The total Acute On Chronic Liver Failure (ACLF) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Market Outlook 

The total Acute On Chronic Liver Failure (ACLF) market size and market size by therapies in Japan is also mentioned. 

Acute On Chronic Liver Failure (ACLF) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Acute On Chronic Liver Failure (ACLF) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Acute On Chronic Liver Failure (ACLF) market uptake by drugs; patient uptake by therapies; and sales of each drug.    


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute On Chronic Liver Failure (ACLF) Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Acute On Chronic Liver Failure (ACLF) key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Acute On Chronic Liver Failure (ACLF) emerging therapies.

Reimbursement Scenario in Acute On Chronic Liver Failure (ACLF)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 

KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Acute On Chronic Liver Failure (ACLF) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Acute On Chronic Liver Failure (ACLF) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 

Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Acute On Chronic Liver Failure (ACLF) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Acute On Chronic Liver Failure (ACLF) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Acute On Chronic Liver Failure (ACLF) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Acute On Chronic Liver Failure (ACLF) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Acute On Chronic Liver Failure (ACLF) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute On Chronic Liver Failure (ACLF) market

Report Highlights

  • In the coming years, Acute On Chronic Liver Failure (ACLF) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Acute On Chronic Liver Failure (ACLF) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Acute On Chronic Liver Failure (ACLF) . Launch of emerging therapies will significantly impact the Acute On Chronic Liver Failure (ACLF) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Acute On Chronic Liver Failure (ACLF)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Acute On Chronic Liver Failure (ACLF) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Acute On Chronic Liver Failure (ACLF) Pipeline Analysis
  • Acute On Chronic Liver Failure (ACLF) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Acute On Chronic Liver Failure (ACLF) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Acute On Chronic Liver Failure (ACLF) Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Acute On Chronic Liver Failure (ACLF) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Acute On Chronic Liver Failure (ACLF) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Acute On Chronic Liver Failure (ACLF) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Acute On Chronic Liver Failure (ACLF) market size during the forecast period (2017-2030)?
  • At what CAGR, the Acute On Chronic Liver Failure (ACLF) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Acute On Chronic Liver Failure (ACLF) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Acute On Chronic Liver Failure (ACLF) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Acute On Chronic Liver Failure (ACLF) ?
  • What is the historical Acute On Chronic Liver Failure (ACLF) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Acute On Chronic Liver Failure (ACLF) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute On Chronic Liver Failure (ACLF) ?
  • Out of all 7MM countries, which country would have the highest prevalent population of Acute On Chronic Liver Failure (ACLF) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Acute On Chronic Liver Failure (ACLF) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Acute On Chronic Liver Failure (ACLF) in the USA, Europe, and Japan?
  • What are the Acute On Chronic Liver Failure (ACLF) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Acute On Chronic Liver Failure (ACLF) ?
  • How many therapies are developed by each company for Acute On Chronic Liver Failure (ACLF) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Acute On Chronic Liver Failure (ACLF) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Acute On Chronic Liver Failure (ACLF) therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Acute On Chronic Liver Failure (ACLF) and their status?
  • What are the key designations that have been granted for the emerging therapies for Acute On Chronic Liver Failure (ACLF) ?
  • What are the global historical and forecasted market of Acute On Chronic Liver Failure (ACLF) ?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Acute On Chronic Liver Failure (ACLF) market
  • To understand the future market competition in the Acute On Chronic Liver Failure (ACLF) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Acute On Chronic Liver Failure (ACLF) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Acute On Chronic Liver Failure (ACLF) market
  • To understand the future market competition in the Acute On Chronic Liver Failure (ACLF) market

"

1 Key Insights

2 Executive Summary of Acute on Chronic Liver Failure

3 SWOT Analysis of Acute-on-Chronic Liver Failure

4 ACLF Epidemiology Overview at a Glance

4.1 Patient Share Distribution of ACLF in 2017

4.2 Patient Share Distribution of ACLF in 2030

5 ACLF Market Overview at a Glance

5.1 Market Share (%) Distribution of ACLF in 2017

5.2 Market Share (%) Distribution of ACLF in 2030

6 Disease Background and Overview

6.1 Introduction

6.2 Heterogeneity of definitions

6.3 Types of ACLF

6.4 Clinical characteristics and pathophysiology

6.5 Diagnosis of ACLF

6.6 ACLF Biomarkers

7 Country-wise Epidemiology of Acute-on-Chronic Liver Failure (ACLF)

7.1 Assumptions and Rationale: 7MM

8 Epidemiology and Patient Population

8.1 Key Findings

8.2 United States

8.2.1 Cases of Acute-on-chronic liver failure (ACLF) in the United States

8.2.2 Cases of ACLF by Grades in the United States

8.2.3 Organ failures associated with ACLF in the United States

8.2.4 Potential precipitating events of ACLF in the United States

8.3 Germany

8.3.1 Cases of Acute-on-chronic liver failure (ACLF) in Germany

8.3.2 Cases of ACLF by Grades in Germany

8.3.3 Organ failures associated with ACLF in Germany

8.3.4 Potential precipitating events of ACLF in Germany

8.4 France

8.4.1 Cases of Acute-on-chronic liver failure (ACLF) in France

8.4.2 Cases of ACLF by Grades in France

8.4.3 Organ failures associated with ACLF in France

8.4.4 Potential precipitating events of ACLF in France

8.5 Italy

8.5.1 Cases of Acute-on-chronic liver failure (ACLF) in Italy

8.5.2 Cases of ACLF by Grades in Italy

8.5.3 Organ failures associated with ACLF in Italy

8.5.4 Potential precipitating events of ACLF in Italy

8.6 Spain

8.6.1 Cases of Acute-on-chronic liver failure (ACLF) in Spain

8.6.2 Cases of ACLF by Grades in Spain

8.6.3 Organ failures associated with ACLF in Spain

8.6.4 Potential precipitating events of ACLF in Spain

8.7 United Kingdom

8.7.1 Cases of Acute-on-chronic liver failure (ACLF) in the UK

8.7.2 Cases of ACLF by Grades in the UK

8.7.3 Organ failures associated with ACLF in the UK

8.7.4 Potential precipitating events of ACLF in the UK

8.8 Japan

8.8.1 Cases of Acute-on-chronic liver failure (ACLF) in Japan

8.8.2 Cases of ACLF by Grades in Japan

8.8.3 Organ failures associated with ACLF in Japan

8.8.4 Potential precipitating events of ACLF in Japan

9 Treatment

9.1 Guidelines

9.1.1 APASL

9.1.2 EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

9.2 Case Study

9.2.1 Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis

9.3 Patient Journey

10 Unmet Needs

11 Emerging Therapies

11.1 Albutein (PE-A 5%): Grifols Therapeutics

11.1.1 Product Description

11.1.2 Clinical Development

11.2 HepaStem: Promethera Biosciences

11.2.1 Product Description

11.2.2 Other Developmental Activities

11.2.3 Clinical Development

11.2.4 Safety and Efficacy

12 Other Promising Candidates

12.1 APZ2: RHEACELL

12.1.1 Product Description

12.1.2 Clinical Development

12.2 VS-01: Versantis

12.2.1 Product Description

12.2.2 Other Developmental Activities

12.3 Livantra: Martin Pharmaceuticals

12.3.1 Product Description

12.3.2 Other developmental activities

12.3.3 Clinical Development

13 Acute-on-chronic liver failure (ACLF): Seven Major Market Analysis

13.1 Key Findings

13.2 Market Size of Acute-on-chronic liver failure in the 7MM

13.3 Market Outlook: 7MM

14 Country-wise Market Analysis: Acute-on-chronic liver failure (ACLF)

14.1 United States

14.1.1 Total Market size of Acute-on-chronic liver failure

14.1.2 Acute-on-chronic liver failure Market Size by Therapies

14.2 EU5 Countries

14.1.1 France

14.1.2 Italy

14.1.3 Spain

14.1.4 United Kingdom

14.2 Japan

14.2.1 Total Market size of Acute-on-chronic liver failure

14.2.2 Acute-on-chronic liver failure Market Size by Therapies

15 Market Drivers

16 Market Barriers

17 Appendix

17.1 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

List of Tables

 Table 1: Summary of ACLF Market, Epidemiology, and Key Events (2017–2030)

Table 2: Characteristics of the available definitions for acute-on-chronic liver failure (ACLF)

Table 3: CLIF Consortium Organ Failure Score: a simplified version of the CLIF-SOFA score

Table 4: Cases of ACLF in the United States (2017–2030)

Table 5: Cases of ACLF by Grades in the United States (2017–2030)

Table 6: Organ failures associated with ACLF in the United States (2017–2030)

Table 7: Potential precipitating events of ACLF in the United States (2017–2030)

Table 8: Cases of ACLF in Germany (2017–2030)

Table 9: Cases of ACLF by Grades in Germany (2017–2030)

Table 10: Organ failures associated with ACLF in Germany (2017–2030)

Table 11: Potential precipitating events of ACLF in Germany (2017–2030)

Table 12: Cases of ACLF in France (2017–2030)

Table 13: Cases of ACLF by Grades in France (2017–2030)

Table 14: Organ failures associated with ACLF in France (2017–2030)

Table 15: Potential precipitating events of ACLF in France (2017–2030)

Table 16: Cases of ACLF in Italy (2017–2030)

Table 17: Cases of ACLF by Grades in Italy (2017–2030)

Table 18: Organ failures associated with ACLF in Italy (2017–2030)

Table 19: Potential precipitating events of ACLF in Italy (2017–2030)

Table 20: Cases of ACLF in Spain (2017–2030)

Table 21: Cases of ACLF by Grades in Spain (2017–2030)

Table 22: Organ failures associated with ACLF in Spain (2017–2030)

Table 23: Potential precipitating events of ACLF in Spain (2017–2030)

Table 24: Cases of ACLF in the UK (2017–2030)

Table 25: Cases of ACLF by Grades in the UK (2017–2030)

Table 26: Organ failures associated with ACLF in the UK (2017–2030)

Table 27: Potential precipitating events of ACLF in the UK (2017–2030)

Table 28: Cases of ACLF in Japan (2017–2030)

Table 29: Cases of ACLF by Grades in Japan (2017–2030)

Table 30: Organ failures associated with ACLF in Japan (2017–2030)

Table 31: Potential precipitating events of ACLF in Japan (2017–2030)

Table 32: PE-A 5%, Clinical Trial Description, 2020

Table 33: HepaStem, Clinical Trial Description, 2020

Table 34: Seven Major Market Size of Acute-on-chronic liver failure in USD Million (2017–2030)

Table 35: The US Market size of Acute-on-chronic liver failure in USD Million (2017–2030)

Table 36: The US market size of Acute-on-chronic liver failure by Therapies in USD Million (2017–2030)

Table 37: Germany Market size of Acute-on-chronic liver failure in USD Million (2017–2030)

Table 38: Germany market size of Acute-on-chronic liver failure by Therapies in USD Million (2017–2030)

Table 39: France Market size of Acute-on-chronic liver failure in USD Million (2017–2030)

Table 40: France market size of Acute-on-chronic liver failure by Therapies in USD Million (2017–2030)

Table 41: Italy Market size of Acute-on-chronic liver failure in USD Million (2017–2030)

Table 42: Italy market size of Acute-on-chronic liver failure by Therapies in USD Million (2017–2030)

Table 43: Spain Market size of Acute-on-chronic liver failure in USD Million (2017–2030)

Table 44: Spain market size of Acute-on-chronic liver failure by Therapies in USD Million (2017–2030)

Table 45: The UK Market size of Acute-on-chronic liver failure in USD Million (2017–2030)

Table 46: The UK market size of Acute-on-chronic liver failure by Therapies in USD Million (2017–2030)

Table 47: Japan Market size of Acute-on-chronic liver failure in USD Million (2017–2030)

Table 48: Japan market size of Acute-on-chronic liver failure by Therapies in USD Million (2017–2030)


List of Figures

Figure 1: SWOT Analysis

Figure 2: Proposed unifying pathogenesis for different types of acute-on-chronic liver failure

Figure 3: The clinical course of cirrhosis

Figure 4: Immune dysfunction in ACLF

Figure 5: Pathogenesis of organ failure in ACLF

Figure 6: Cases of ACLF in the United States (2017–2030)

Figure 7: Cases of ACLF by Grades in the United States (2017–2030)

Figure 8: Organ failures associated with ACLF in the United States (2017–2030)

Figure 9: Potential precipitating events of ACLF in the United States (2017–2030)

Figure 10: Cases of ACLF in Germany (2017–2030)

Figure 11: Cases of ACLF by Grades in Germany (2017–2030)

Figure 12: Organ failures associated with ACLF in Germany (2017–2030)

Figure 13: Potential precipitating events of ACLF in Germany (2017–2030)

Figure 14: Cases of ACLF in France (2017–2030)

Figure 15: Cases of ACLF by Grades in France (2017–2030)

Figure 16: Organ failures associated with ACLF in France (2017–2030)

Figure 17: Potential precipitating events of ACLF in France (2017–2030)

Figure 18: Cases of ACLF in Italy (2017–2030)

Figure 19: Cases of ACLF by Grades in Italy (2017–2030)

Figure 20: Organ failures associated with ACLF in Italy (2017–2030)

Figure 21: Potential precipitating events of ACLF in Italy (2017–2030)

Figure 22: Cases of ACLF in Spain (2017–2030)

Figure 23: Cases of ACLF by Grades in Spain (2017–2030)

Figure 24: Organ failures associated with ACLF in Spain (2017–2030)

Figure 25: Potential precipitating events of ACLF in Spain (2017–2030)

Figure 26: Cases of ACLF in the UK (2017–2030)

Figure 27: Cases of ACLF by Grades in the UK (2017–2030)

Figure 28: Organ failures associated with ACLF in the UK (2017–2030)

Figure 29: Potential precipitating events of ACLF in the UK (2017–2030)

Figure 30: Cases of ACLF in Japan (2017–2030)

Figure 31: Cases of ACLF by Grades in Japan (2017–2030)

Figure 32: Organ failures associated with ACLF in Japan (2017–2030)

Figure 33: Potential precipitating events of ACLF in Japan (2017–2030)

Figure 34: Algorithm for management of acute-on-chronic liver failure

Figure 35: Patient Journey for ACLF

Figure 36: Unmet needs for ACLF

Figure 37: Seven Major Market Size of Acute-on-chronic liver failure in USD Million (2017–2030)

Figure 38: Market Size of Acute-on-chronic liver failure in the United States, USD Millions (2017–2030)

Figure 39: The US market size of Acute-on-chronic liver failure by therapies in USD Million (2017–2030)

Figure 40: Market Size of Acute-on-chronic liver failure in Germany, USD Millions (2017–2030)

Figure 41: Germany market size of Acute-on-chronic liver failure by therapies in USD Million (2017–2030)

Figure 42: Market Size of Acute-on-chronic liver failure in France, USD Millions (2017–2030)

Figure 43: France market size of Acute-on-chronic liver failure by therapies in USD Million (2017–2030)

Figure 44: Market Size of Acute-on-chronic liver failure in Italy, USD Millions (2017–2030)

Figure 45: Italy market size of Acute-on-chronic liver failure by therapies in USD Million (2017–2030)

Figure 46: Market Size of Acute-on-chronic liver failure in Spain, USD Millions (2017–2030)

Figure 47: Spain market size of Acute-on-chronic liver failure by therapies in USD Million (2017–2030)

Figure 48: Market Size of Acute-on-chronic liver failure in the UK, USD Millions (2017–2030)

Figure 49: The UK market size of Acute-on-chronic liver failure by therapies in USD Million (2017–2030)

Figure 50: Market Size of Acute-on-chronic liver failure in Japan, USD Millions (2017–2030)

Figure 51: Japan market size of Acute-on-chronic liver failure by therapies in USD Million (2017–2030)

Figure 52: Market drivers for ACLF

Figure 53: Market Barriers for ACLF

Grifols Therapeutics

RHEACELL

Versantis

Martin Pharmaceuticals

  • Tags:
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...
  • Acute On Chronic Liver Failure (ACL...

Forward to Friend

Need A Quote